# H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...

> **NCT02206464** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 30 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** A/Shanghai/02/2013 (H7N9) MIV
- **BIOLOGICAL:** VRC-FLUDNA071-00-VP

## Key facts

- **NCT ID:** NCT02206464
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-29
- **Primary completion:** 2016-01-07
- **Final completion:** 2016-01-07
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02206464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02206464, "H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02206464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*